Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.
Peters KB, Alford C, Heltemes A, Savelli A, Landi DB, Broadwater G, Desjardins A, Johnson MO, Low JT, Khasraw M, Ashley DM, Friedman HS, Patel MP.
Peters KB, et al. Among authors: friedman hs.
Neurooncol Pract. 2023 Oct 14;11(2):199-204. doi: 10.1093/nop/npad068. eCollection 2024 Apr.
Neurooncol Pract. 2023.
PMID: 38496920
Free article.